ArticleNeurology2026
Neuropsychiatric Symptoms in Patients With Pathologically Confirmed Comorbid Alzheimer Disease and Frontotemporal Lobar Degeneration.
Article in Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND AND
objectivesLittle is known about the clinical presentation in patients with comorbid Alzheimer disease neuropathologic change (ADNC) and frontotemporal lobar degeneration (FTLD) neuropathology, despite frequent comorbidity of neurodegenerative diseases on autopsy. In other neurodegenerative conditions, multiple pathologies alter the presentation of neuropsychiatric symptoms, complicating clinical care. We examined whether neuropsychiatric symptoms differ in patients with comorbid ADNC/FTLD compared with patients with each pathology alone.
methodsThis was a retrospective examination of data from 29 US Alzheimer's Disease Research Centers, obtained through the National Alzheimer's Coordinating Center September 2024 data freeze. Patients with intermediate-to-high ADNC and/or FTLD neuropathology on autopsy were included. Neuropsychiatric symptoms were apathy, depressed mood, visual/auditory hallucinations, delusions, disinhibition, irritability, agitation, personality change, REM sleep behavior disorder, and anxiety, identified by clinicians at patients' final visit. Logistic regression models examined the odds of the comorbid vs single pathology groups expressing each neuropsychiatric symptom, controlling for age, sex, race, ethnicity, education, and interval between first visit and death.
resultsData from 919 patients (mean age 81 years [SD 12 years], 49% female) were analyzed. Ninety-four patients (mean age 84 years [SD 10 years], 46% female) had comorbid ADNC/FTLD pathology, 590 had ADNC only, and 235 had FTLD only. Compared with the FTLD-only group, patients in the comorbid ADNC/FTLD group were more likely to present with anxiety (odds ratio [OR] 3.11, 95% CI 1.38-6.98, DISCUSSION: Comorbid presence of ADNC and FTLD neuropathology, compared with each pathology alone, was associated with a greater likelihood of presenting with known neuropsychiatric symptoms of the other disease, irrespective of patients' clinical syndrome. Findings highlight the potential clinical diagnostic value of antemortem behavioral symptoms in identifying patients with comorbid pathology, although conclusions are limited by the cross-sectional nature of the neuropsychiatric data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.